Using recently collected data in the United States, this lecture will focus on kratom pharmacology and product types, use patterns and effects, consumer demographics and use motivations, and health impacts including physical dependence or use disorder.

1. Describe the different types of kratom products most often used in the US and understand their differences;
2. Describe the basic pharmacology of kratom;
3. Define the motivations for kratom use and acute effects from use;
4. Define the current regulatory, legal, and research state of kratom;
5. Evaluate and assess patients who use kratom more comprehensively, including evaluating the difference between physical dependence and substance use disorder.

ACCREDITATION:
This actvity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association and The American Osteopathic Academy of Addiction Medicine (AOAAM). The American Osteopathic Association is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT HOURS:
The American Osteopathic Association designates this other activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

DISCLOSURE AND CONFLICT OF INTEREST RESOLUTION:
All conflicts of interest of any individual(s) in a position to control the content of this CME activity will be identified and resolved prior to this educational activity being provided. Disclosure about provider and faculty relationships, or the lack thereof, will be provided to learners.

Funding for this initiative was made possible (in part) by grant no. 1H79TI085588-02 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.